Using Enstilar with Enbrel or Humira for treating plaque psoriasis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of Enstilar, a topical foam, when used in conjunction with etanercept (Enbrel) or adalimumab (Humira) for patients with chronic plaque psoriasis. Participants will receive Enstilar once daily for the first four weeks, followed by every other day for an additional twelve weeks. The study focuses on patients who have been on etanercept or adalimumab for at least 24 weeks and have a body surface area involvement of 2-10%. The goal is to assess improvements in skin condition and overall patient assessment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female adult ≥ 18 years of age;
* Diagnosis of chronic plaque-type
* Patient with 2-10% BSA
* Physician Global Assessment of 2 or greater
* Patient has been treated with etanercept or adalimumab for a minimum of 24 weeks

Exclusion Criteria:

* ˂2 or \>10% BSA
* PGA \<2
* Patient not receiving etanercept or adalimumab, or receiving etanercept or adalimumab \<24weeks

Where it's running

• Psoriasis Treatment Center of Central New Jersey
  East Windsor, New Jersey, United States Recruiting

Study contacts

• Study coordinator: Jerry Bagel, MD
• Email: dreamacres1@aol.com
• Phone: 6094434500

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HB0017 Injection safety and PK in low-weight adults at different injection sites

  This early-phase study tests a single subcutaneous HB0017 injection in healthy, low-weight adults and compares how the body processes the drug when injected at different sites.

  Recruiting Phase 1 Huabo Biopharm Co., Ltd. · Hangzhou, Zhejiang · NCT07920861

• MK-8644: first-in-human test in healthy people and people with psoriasis

  This early-phase study tests MK-8644 versus placebo in healthy volunteers and people with psoriasis to see if it is safe and tolerable.

  Recruiting Phase 1 Merck Sharp & Dohme LLC · Melbourne, Victoria · NCT07850310

• Add-on anti-inflammatory therapy for adults with depression and high inflammation

  This study tests whether adalimumab, given with your regular antidepressant Lexapro, can improve depressive symptoms in adults with major depressive disorder and high inflammation.

  Recruiting Phase 2 University of Pennsylvania · Philadelphia, Pennsylvania · NCT07845604

• Colonic delivery of two antibodies to see if they reach the bloodstream in healthy people

  This early study tests whether guselkumab and adalimumab given directly into the colon can enter the body in healthy adults.

  Recruiting Phase 1 Surmount Services, Inc. · Maroochydore, Queensland · NCT07788807

• Is XJH05 Ointment Effective for Plaque Psoriasis?

  This study tests whether the XJH05 ointment can help people with plaque psoriasis compare to a calcipotriol ointment.

  Recruiting Xijing Hospital · Xi'an, Shaanxi · NCT07780929

• Guselkumab after Ustekinumab in adults with moderate-to-severe psoriasis in routine care

  This study looks at how well guselkumab works for people with moderate-to-severe psoriasis after switching from ustekinumab in everyday clinical practice.

  Recruiting Janssen-Cilag Kft. · Budapest · NCT07746583

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.